SERODUS approaches collaborations and licensing deals with the aim of reflecting the needs and aligning the contributions of both partners. 


Are you looking for drug candidates in type 2 diabetes and its comorbidities, for opportunities that address diseases of unmet medical need and have the potential to revolutionize the standard of care?

Serodus’ business model is based on out-licensing its pipeline programs to international pharma, specialty pharma and expert biotech companies after showing “proof-of-concept”.

We welcome inquiries from potential partners wishing to discuss potential collaborations with us.

Partnerships are an important part of Serodus growth strategy. 

To inquire about partnering opportunities, please send an email to Eva Steiness, CEO at:

What makes Serodus an attractive partner?

Serodus is a virtual drug-development company and therefore are we “assets” oriented.

Management has a proven track record of bringing new compounds to the market and of closing major partnering agreements.

If you partner with us early, you can influence the optimal development strategy.